US Patent

US12551447 — Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists

Formulation · Assigned to Sumitomo Pharma Co Ltd · Expires 2042-11-05 · 16y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects combination solid oral dosage forms containing a specific hormone antagonist and hormone replacement medicaments.

USPTO Abstract

The present disclosure includes combination solid oral dosage forms having 40 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and hormone replacement medicaments. Also provided are processes for making and using the solid oral dosage forms.

Drugs covered by this patent

Patent Metadata

Patent number
US12551447
Jurisdiction
US
Classification
Formulation
Expires
2042-11-05
Drug substance claim
No
Drug product claim
Yes
Assignee
Sumitomo Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.